A Phase 1 Trial of BNC105P & Ibrutinib in Patients with Relapsed/Refractory chronic lymphocytic leukemia (CLL)

Trial Profile

A Phase 1 Trial of BNC105P & Ibrutinib in Patients with Relapsed/Refractory chronic lymphocytic leukemia (CLL)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs BNC 105 (Primary) ; Ibrutinib (Primary)
  • Indications B-cell leukaemia; Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top